What is MAIA Biotechnology, Inc. (MAIA) stock price today?

MAIA Biotechnology, Inc. (MAIA) is currently trading at $1.18, down 3.28% today.

What is MAIA P/E ratio?

MAIA Biotechnology, Inc.'s P/E ratio is -1.88. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is MAIA return on equity (ROE)?

MAIA Biotechnology, Inc.'s return on equity (ROE) is -211.15%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is MAIA Biotechnology, Inc.'s market cap?

MAIA Biotechnology, Inc. has a market capitalization of $71.74M.

AMEX · Biotechnology

MAIA Biotechnology, Inc. (MAIA) Stock

$1.18 -3.28% AMEX: MAIA Healthcare

Valuation

Metric	Value
Price	$1.18
Market Cap	$71.74M
P/E Ratio	-1.88
P/B Ratio	3.50
P/S Ratio	0.00
EPS (TTM)	$-0.70
52-Week High	$3.19
52-Week Low	$0.87
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-211.15%
ROA	-95.06%
ROCE	-131.68%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	1.67

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-8.0M	$-16.0M	$-20.0M	$-17.0M	$-24.0M
Net Profit	$-13.0M	$-16.0M	$-20.0M	$-23.0M	$-22.0M
EPS	$-1.18	$-1.70	$-1.49	$-1.05	$-0.70
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$11.0M	$12.0M	$8.0M	$10.0M	$10.0M
Total Liabilities	$2.0M	$4.0M	$7.0M	$7.0M	$7.0M
Cash	$11.0M	$11.0M	$7.0M	$10.0M	$8.7B
Borrowings	$0	$0	$0	$0	$0

Latest News

MAIA Biotechnology Says Ateganosine Shows 90.5% Disease Control Rate in Phase 2 Expansion Trial MT Newswires · Jul 8, 2026 MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial GlobeNewswire · Jul 8, 2026 MAIA Biotechnology Completes Part C International Enrollment for Phase 2 Ateganosine Trial MT Newswires · Jun 25, 2026 MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer GlobeNewswire · Jun 25, 2026 MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-4.0M	$-12.0M	$-13.0M	$-16.0M	$-19.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$1.0M	$-1.0M	$-2.0M	$-1.0M	$-1.0M
Net Cash Flow	$10.0M	$0	$-4.0M	$2.0M	$-1.0M
Free Cash Flow	$-4.0M	$-12.0M	$-13.0M	$-16.0M	$-19.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.13
EV / EBITDA	-2.62
FCF Yield	-31.19%
Quick Ratio	4.51
Interest Coverage	0.00
Return 1Y	-15.20%
Return 3Y	-33.79%
Return 5Y	—

Ownership

Insiders Held14.39%

Institutions Held21.63%

Institutions Float Held25.27%

Institutional Holder	Shares	Report Date
Solas Capital Management, LLC	4,297,004	2026-03-31
Alyeska Investment Group, L.p.	2,500,000	2026-03-31
Vanguard Capital Management LLC	2,074,045	2026-03-31
683 Capital Management LLC	1,066,666	2026-03-31
Centric Wealth Management	796,723	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANVSAnnovis Bio, Inc.	$1.15	-4.96%	-0.67	$48.92M	0.00%
BCAB	$1.74	+0.00%	-0.12	$2.88M	0.00%
CALCCalciMedica, Inc.	$1.21	-5.12%	-0.21	$3.79M	0.00%
CELUCelularity Inc.	$1.48	-5.13%	-0.51	$42.84M	0.00%
ELUTElutia, Inc.	$0.78	-4.79%	0.60	$34.65M	0.00%

About MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is led by CEO Vlad Vitoc, employs 13 people, headquartered in US, publicly traded since 2022.

MAIA Biotechnology, Inc. (MAIA) stock trades at $1.18 with a market capitalization of $71.74M. The stock is valued at a price-to-earnings (P/E) ratio of -1.88, price-to-book of 3.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.87 and $3.19, and currently trades 63.0% below its 52-week high.

On profitability, MAIA Biotechnology, Inc. generates a return on equity (ROE) of -211.15%, return on capital employed of -131.68%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1182.62 +0.28% JNJ Johnson & Johnson $263.73 +0.88% ABBV AbbVie Inc. $281.04 +1.65% MRK Merck & Company, Inc. Common Stock (new) $145.45 -0.10% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.52 -0.21% NVS Novartis AG $143.84 +0.06% AZN AstraZeneca PLC $158.58 -0.39% TMO Thermo Fisher Scientific Inc $662.24 +0.64% AMGN Amgen Inc. $417.57 +0.65% GILD Gilead Sciences, Inc. $150.43 -0.49% ABT Abbott Laboratories $101.82 +2.23% NVO Novo Nordisk A/S $38.64 +0.00%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides